in vivo-jetPEI® 0.5 mL
상품정보
Introduction
Relevant Applications
- RNA | DNA vaccination
- Gene therapy
- RNA | DNA therapeutics
- Genome editing
- Oncology treatment
- Pulmonary diseases
- Protein replacement therapy
- In vivo proof-of-concept studies
- Academic research
Relevant Process Steps
- Drug product formulation
- Delivery | transfection
Performance
Versatile
in vivo-jetPEI® is effective for the delivery of nucleic acids (DNA, siRNA, miRNA, shRNA, other oligonucleotides) in any animal model (mouse, rat, rabbit, llama, monkey, etc.) and can be used to target a wide range of organs by systemic and local administration. The route of injection largely determines which organs are targeted, allowing scientists to modulate biodistribution according to their needs and objectives (Figure 1). When delivering pDNA, cell-specific promoters can also be combined with a local injection route to restrict expression to a specific organ | tissue.
Figure 1: in vivo-jetPEI® Leads to Efficient Gene Expression in Different Organs Depending on the Administration Route
Note. Complexes were formed using 40 or 100 µg of Luciferase-expressing plasmid and in vivo-jetPEI® at an N | P ratio of 8, in 200 or 500 µL of 5% glucose and injected either through the retro-orbital sinus (IV) or intraperitoneally (IP), respectively. Different organs were extracted 24 hours after injection, and (A) luciferase expression was measured or (B) live imaging was performed using the IVIS system (Perkin Elmer).
Time-Saving
in vivo-jetPEI® is a ready-to-use reagent with a straightforward protocol, saving time and cost on formulation. The nucleic acid and in vivo-jetPEI® complexes are prepared in just two steps and are ready to be injected into the animal model within 15 minutes (Figure 2).
Figure 2: Two-Step Protocol for In Vivo Delivery of in vivo-jetPEI®
Note. This protocol is suitable for direct injection of nucleic acid | in vivo-jetPEI® complexes through any local or systemic administration route.
Seamless Transition From Fundamental Research to Human Clinical Trials
In addition to being used for in vivo functional and proof-of-concept studies, in vivo-jetPEI® has been chosen as a delivery vehicle for several drug development programs thanks to its reliability, safety, and efficacy. Several preclinical studies and human clinical trials are currently underway for cancer therapy, vaccination, and immunization using the GMP-compliant grade of in vivo-jetPEI® (Table 1).
Table 1: Overview of in vivo-jetPEI® Transfection Reagent Offering for Non-Viral In Vivo Delivery
| Characteristics | in vivo-jetPEI® | in vivo-jetPEI® GMP |
|---|
| Product pack size | 0.1 mL | 0.5 mL | bulk quantities | 10 g |
| Quality controls (QC) | Standard QCs | Validated QCs according to US and | or European Pharmacopeia assessing identity, potency, purity, and safety |
| Quality and regulatory documents |
|
|
| Manufacturing environment | According to ISO 9001 2015 | According to GMP guidelines |
Note. in vivo-jetPEI® is suitable for applications from fundamental research to proof-of-concept and preclinical studies. A GMP-compliant grade is also available to meet the quality and regulatory requirements of human clinical trials.
구매정보
in vivo-jetPEI® 0.5 mL